CCL24 and Fibrosis: A Narrative Review of Existing Evidence and Mechanisms
Tissue fibrosis results from a dysregulated and chronic wound healing response accompanied by chronic inflammation and angiogenesis. Regardless of the affected organ, fibrosis shares the following common hallmarks: the recruitment of immune cells, fibroblast activation/proliferation, and excessive e...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-01-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/14/2/105 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832588837345296384 |
|---|---|
| author | Raanan Greenman Chris J. Weston |
| author_facet | Raanan Greenman Chris J. Weston |
| author_sort | Raanan Greenman |
| collection | DOAJ |
| description | Tissue fibrosis results from a dysregulated and chronic wound healing response accompanied by chronic inflammation and angiogenesis. Regardless of the affected organ, fibrosis shares the following common hallmarks: the recruitment of immune cells, fibroblast activation/proliferation, and excessive extracellular matrix deposition. Chemokines play a pivotal role in initiating and advancing these fibrotic processes. CCL24 (eotaxin-2) is a chemokine secreted by immune cells and epithelial cells, which promotes the trafficking of immune cells and the activation of profibrotic cells through CCR3 receptor binding. Higher levels of CCL24 and CCR3 were found in the tissue and sera of patients with fibro-inflammatory diseases, including primary sclerosing cholangitis (PSC), systemic sclerosis (SSc), and metabolic dysfunction-associated steatohepatitis (MASH). This review delves into the intricate role of CCL24 in fibrotic diseases, highlighting its impact on fibrotic, immune, and vascular pathways. We focus on the preclinical and clinical evidence supporting the therapeutic potential of blocking CCL24 in diseases that involve excessive inflammation and fibrosis. |
| format | Article |
| id | doaj-art-5bfea6307b6f44c1abfae16b2236a509 |
| institution | Kabale University |
| issn | 2073-4409 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cells |
| spelling | doaj-art-5bfea6307b6f44c1abfae16b2236a5092025-01-24T13:26:41ZengMDPI AGCells2073-44092025-01-0114210510.3390/cells14020105CCL24 and Fibrosis: A Narrative Review of Existing Evidence and MechanismsRaanan Greenman0Chris J. Weston1Chemomab Therapeutics Ltd., Tel Aviv 6158002, IsraelDepartment of Immunology and Immunotherapy, School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham, Birmingham B15 2TT, UKTissue fibrosis results from a dysregulated and chronic wound healing response accompanied by chronic inflammation and angiogenesis. Regardless of the affected organ, fibrosis shares the following common hallmarks: the recruitment of immune cells, fibroblast activation/proliferation, and excessive extracellular matrix deposition. Chemokines play a pivotal role in initiating and advancing these fibrotic processes. CCL24 (eotaxin-2) is a chemokine secreted by immune cells and epithelial cells, which promotes the trafficking of immune cells and the activation of profibrotic cells through CCR3 receptor binding. Higher levels of CCL24 and CCR3 were found in the tissue and sera of patients with fibro-inflammatory diseases, including primary sclerosing cholangitis (PSC), systemic sclerosis (SSc), and metabolic dysfunction-associated steatohepatitis (MASH). This review delves into the intricate role of CCL24 in fibrotic diseases, highlighting its impact on fibrotic, immune, and vascular pathways. We focus on the preclinical and clinical evidence supporting the therapeutic potential of blocking CCL24 in diseases that involve excessive inflammation and fibrosis.https://www.mdpi.com/2073-4409/14/2/105CCL24CCR3chemokineeotaxin-2fibrosissystemic sclerosis |
| spellingShingle | Raanan Greenman Chris J. Weston CCL24 and Fibrosis: A Narrative Review of Existing Evidence and Mechanisms Cells CCL24 CCR3 chemokine eotaxin-2 fibrosis systemic sclerosis |
| title | CCL24 and Fibrosis: A Narrative Review of Existing Evidence and Mechanisms |
| title_full | CCL24 and Fibrosis: A Narrative Review of Existing Evidence and Mechanisms |
| title_fullStr | CCL24 and Fibrosis: A Narrative Review of Existing Evidence and Mechanisms |
| title_full_unstemmed | CCL24 and Fibrosis: A Narrative Review of Existing Evidence and Mechanisms |
| title_short | CCL24 and Fibrosis: A Narrative Review of Existing Evidence and Mechanisms |
| title_sort | ccl24 and fibrosis a narrative review of existing evidence and mechanisms |
| topic | CCL24 CCR3 chemokine eotaxin-2 fibrosis systemic sclerosis |
| url | https://www.mdpi.com/2073-4409/14/2/105 |
| work_keys_str_mv | AT raanangreenman ccl24andfibrosisanarrativereviewofexistingevidenceandmechanisms AT chrisjweston ccl24andfibrosisanarrativereviewofexistingevidenceandmechanisms |